|
Q2 2026
|
15 |
1,039,008
|
Veradermics, Inc., ZBIO, CRSP, Avalyn Pharma, Inc
|
13F-HR
|
8/12/2026 |
000119312526347065 |
|
Q1 2026
|
14 |
915,442
|
ACLX, Veradermics, Inc., ZBIO, CRSP
|
13F-HR
|
5/14/2026 |
000119312526224136 |
|
Q4 2025
|
13 |
706,377
|
ZBIO, ACLX, CRSP, DSGN
|
13F-HR
|
2/12/2026 |
000119312526048808 |
|
Q3 2025
|
12 |
691,412
|
ACLX, CRSP, ZBIO, MLYS
|
13F-HR
|
11/12/2025 |
000119312525277769 |
|
Q2 2025
|
13 |
461,376
|
ACLX, SPRY, CRSP, ZBIO
|
13F-HR
|
8/14/2025 |
000095012325008422 |
|
Q1 2025
|
12 |
389,283
|
ACLX, SPRY, MLYS, ZBIO
|
13F-HR
|
5/13/2025 |
000095012325004926 |
|
Q4 2024
|
11 |
410,085
|
ACLX, SPRY, CRSP, DSGN
|
13F-HR
|
2/13/2025 |
000095012325002049 |
|
Q3 2024
|
11 |
498,735
|
ACLX, Zenas BioPharma, Inc, SPRY, CRSP
|
13F-HR
|
11/13/2024 |
000095012324011277 |
|
Q2 2024
|
9 |
319,402
|
ACLX, CRSP, SPRY, Alumis Inc.
|
13F-HR
|
8/13/2024 |
000095012324008225 |
|
Q1 2024
|
6 |
364,089
|
ACLX, CRSP, SPRY, NKTX
|
13F-HR
|
5/13/2024 |
000191026424000003 |
|
Q4 2023
|
5 |
238,157
|
ACLX, SPRY, DSGN, MLYS
|
13F-HR
|
2/12/2024 |
000191026424000001 |
|
Q3 2023
|
6 |
195,121
|
ACLX, MLYS, DSGN, SPRY
|
13F-HR
|
11/13/2023 |
000191026423000007 |
|
Q2 2023
|
6 |
231,908
|
ACLX, DSGN, MLYS, SPRY
|
13F-HR
|
8/10/2023 |
000191026423000005 |
|
Q1 2023
|
6 |
268,461
|
ACLX, DSGN, MLYS, SPRY
|
RESTATEMENT
|
5/19/2023 |
000191026423000003 |
|
Q4 2022
|
5 |
273,945
|
ACLX, DSGN, SPRY, NKTX
|
13F-HR
|
2/8/2023 |
000191026423000001 |
|
Q3 2022
|
4 |
218,746
|
ACLX, DSGN, NKTX, EFTR
|
13F-HR
|
11/8/2022 |
000191026422000004 |
|
Q2 2022
|
4 |
204,325
|
ACLX, DSGN, NKTX, EFTR
|
13F-HR
|
8/1/2022 |
000191026422000003 |
|
Q1 2022
|
3 |
195,335
|
DSGN, ACLX, EFTR
|
13F-HR
|
5/10/2022 |
000191026422000002 |
|
Q4 2021
|
2 |
176,950
|
DSGN, EFTR
|
13F-HR
|
2/14/2022 |
000191026422000001 |